HRP20220571T1 - Spoj piridilpiridona - Google Patents

Spoj piridilpiridona Download PDF

Info

Publication number
HRP20220571T1
HRP20220571T1 HRP20220571TT HRP20220571T HRP20220571T1 HR P20220571 T1 HRP20220571 T1 HR P20220571T1 HR P20220571T T HRP20220571T T HR P20220571TT HR P20220571 T HRP20220571 T HR P20220571T HR P20220571 T1 HRP20220571 T1 HR P20220571T1
Authority
HR
Croatia
Prior art keywords
pyridyl
pyridin
oxo
alkyl
pharmaceutically acceptable
Prior art date
Application number
HRP20220571TT
Other languages
English (en)
Inventor
Johan LINDSTRÖM
Rickard Forsblom
Tobias Ginman
Fredrik Rahm
Jenny Viklund
Original Assignee
Sprint Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience Ab filed Critical Sprint Bioscience Ab
Publication of HRP20220571T1 publication Critical patent/HRP20220571T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Spoj formule (I) [image] gdje X je C=O ili veza; R1 je odabrano od H, C1-C3alkila, C1-C3haloalkila, C1-C3alkoksiC1-C3alkila, C3-C6cikloalkila, C3-C6ciklohaloalkila, C1-C3alkoksi, C1-C3haloalkoksi, C3-C6cikloalkoksimetila, N-C1-C3alkilamino, N,N-diC1-C3alkilamino, 1-pirolidinila, 1-piperidinila i 1-azetidinila, pod uvjetom kada R1 je C1-C3alkoksi, C1-C3haloalkoksi, N-C1-C3alkilamino N,N-diC1-C3alkilamino, 1-pirolidinil, 1-piperidinil ili 1-azetidinil, tada X je C=O; R2 je odabrano od vodika, C1-C3haloalkila i C1-C3alkila; R3 je odabrano od A, fenila i monocikličnog heteroarila, navedeni fenil i navedeni heteroaril su po izboru supstituirani sa jedim ili više R4, R5, R6 i R7; R4, R5, R6 i R7 su nezavisno odabrani od halo, C1-C6alkila, C3-C6cikloalkila, C1-C6alkoksi, C1-C3haloalkoksi, N,N-diC1-C3alkilamino, N-C1-C3alkilamino, 1-azetidinila, C1-C6haloalkila, amino, NHSO2R8, SO2R9 i hidroksi; R8 je C1-C3haloalkil ili C1-C3alkil; R9 je odabrano od R10, C1-C6alkila, amino, N-C1-C3alkilamino, N,N-diC1-C3alkilamino i C1-C3alkoksiC1-C3alkila, navedeni C1-C6alkil i navedeni C1-C3alkoksiC1-C3alkil su po izboru supstituirani sa jednim R10 i/ili jednim ili više halo; R10 je odabrano od fenila, monocikličnog heteroarila, C3-C6cikloalkila, heterociklila, svaki je po izboru supstituiran sa jednim ili više R11; R11 je odabrano od halo, C1-C3alkoksiC1-C3alkila, amino, N-C1-C3alkilamino, N,N-diC1-C3alkilamino, C1-C3haloalkoksi, C1-C3alkoksi, C3-C6cikloalkila, C1-C3haloalkila i C1-C3alkila; A predstavlja [image] R12 je odabrano od vodika, halo, COR13, C1-C6alkila, C1-C3alkoksiC1-C3alkila, C1-C6alkoksi, C3-C6cikloalkila, C1-C3cijanoalkila, C1-C3haloalkila; R13 je odabrano od C1-C3alkoksi, N-C1-C3alkilamino, N,N-diC1-C3alkilamino, 1-pirolidinila, 1-piperidinila i 1-azetidinila; Y predstavlja CH2, S, SO, SO2, NR14, NCOR9, NCOOR15, NSO2R9, NCOCH2R9, O, ili vezu; R14 je odabrano od H, C1-C3haloalkila, C1-C3alkoksiC1-C3alkila, C1-C3alkila, C3-C6cikloalkila; R15 je odabrano od R10, C1-C6alkila i C1-C3alkoksiC1-C3alkila, navedeni C1-C6alkil i navedeni C1-C3alkoksiC1-C3alkila su po izboru supstituirani sa jednim R10 i/ili jednim ili više halo; ili farmaceutski prihvatljiva sol istog.
2. Spoj prema patentnom zahtjevu 1, gdje R1 je odabrano od H, C1-C3alkila, C1-C3alkoksi, C1-C3haloalkoksi, C1-C3alkoksiC1-C3alkila, N,N-diC1-C3alkilamino, 1-pirolidinila i C3-C6cikloalkila; ili farmaceutski prihvatljiva sol istog.
3. Spoj prema patentnom zahtjevu 1 ili 2, gdje R3 je odabrano od A, fenila i monocikličnog heteroarila odabranog od piridila, tienila, furila, pirimidinila i pirazolila, gdje navedeni fenil i navedeni heteroaril su po izboru supstituirani sa R4 i/ili R5; ili farmaceutski prihvatljiva sol istog.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, gdje R4, R5, R6 i R7 su nezavisno odabrani od fluoro, kloro, C1-C3alkila, C3-C6cikloalkila, C1-C3fluoroalkila i SO2R9; ili farmaceutski prihvatljiva sol istog.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, gdje R12 je odabrano od vodika, C1-C3alkila, C1-C3alkoksiC1-C3alkila, C1-C3haloalkila i C3-C6cikloalkila; ili farmaceutski prihvatljiva sol istog.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, gdje R9 je odabrano od R10, N,N-diC1-C3alkilamino i metoksiC1-C3alkila, navedeni C1-C3alkil je po izboru supstituiran sa jednim R10; ili farmaceutski prihvatljiva sol istog.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, gdje R10 je odabrano od fenila, piridila, imidazolila, izoksazolila, oksazolila, ciklopropila, ciklopentila, pirolidinila, tetrahidrofurila, svaki je po izboru supstituiran sa jednim ili više metila i/ili fluoro; ili farmaceutski prihvatljiva sol istog.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, gdje R3 je odabrano od [image] [image] [image] ili farmaceutski prihvatljiva sol istog.
9. Spoj prema patentnom zahtjevu 1, gdje R1 je odabrano od H, metila, metoksi, metoksimetila, N,N-dimetilamino, 1-pirolidinila i ciklopropila; R2 je vodik; i R3 je odabrano od [image] [image] ili farmaceutski prihvatljiva sol istog.
10. Spoj prema patentnom zahtjevu 1, pri čemu je navedeni spoj N-[4-[2-(2-klorofenil)-6-okso-1H-piridin-4-il]-2-piridil]acetamid; 4-(2-Amino-4-piridil)-6-(3-piridil)-1H-piridin-2-on; 4-(2-Amino-4-piridil)-6-(2-klorofenil)-1H-piridin-2-on; N-[4-[2-(2-klorofenil)-6-okso-1H-piridin-4-il]-2-piridil]-2-metoksi-acetamid; N-[4-[2-okso-6-[2-(trifluorometil)-1-piperidil]-1H-piridin-4-il]-2-piridil]acetamid; N-[4-[2-okso-6-[2-(trifluorometil)-1-piperidil]-1H-piridin-4-il]-2-piridil]ciklopropankarboksamid; N-[4-[2-okso-6-[3-(trifluorometil)morfolin-4-il]-1H-piridin-4-il]-2-piridil]acetamid; metil N-[4-[2-(2-klorofenil)-6-okso-1H-piridin-4-il]-2-piridil]karbamat; metil N-[4-[2-[1-etil-3-(trifluorometil)pirazol-4-il]-6-okso-1H-piridin-4-il]-2-piridil]karbamat; metil N-[4-[2-okso-6-[2-(trifluorometil)-3-piridil]-1H-piridin-4-il]-2-piridil]karbamat; metil N-[4-[2-okso-6-[2-(trifluorometil)fenil]-1H-piridin-4-il]-2-piridil]karbamat; N-[4-[2-okso-6-[2-(trifluorometil)fenil]-1H-piridin-4-il]-2-piridil]acetamid; N-[4-[2-(4-metil-3-piridil)-6-okso-1H-piridin-4-il]-2-piridil]acetamid; N-[4-[2-okso-6-[2-(trifluorometil)-3-piridil]-1H-piridin-4-il]-2-piridil]acetamid; N-[4-[2-[1-etil-3-(trifluorometil)pirazol-4-il]-6-okso-1 H-piridin-4-il]-2-piridil]acetamid; metil N-[4-[2-okso-6-[3-(trifluorometil)morfolin-4-il]-1H-piridin-4-il]-2-piridil] karbamat; metil N-[4-[2-okso-6-[2-(trifluorometil)-1-piperidil]-1 H-piridin-4-il]-2-piridil]karbamat; N-[4-[2-(3-ciklopropilmorfolin-4-il)-6-okso-1H-piridin-4-il]-2-piridil]acetamid; N-[4-[2-[4-etilsulfonil-2-(trifluorometil)piperazin-1-il]-6-okso-1H-piridin-4-il]-2-piridil]acetamid; N-[4-[2-(2-metil-3-piridil)-6-okso-1H-piridin-4-il]-2-piridil]acetamid; N-[4-[2-okso-6-[4-(trifluorometil)-3-tienil]-1H-piridin-4-il]-2-piridil]acetamid; 1,1-Dimetil-3-[4-[2-okso-6-[2-(trifluorometil)fenil]-1H-piridin-4-il]-2-piridil]urea; N-[4-[2-okso-6-[2-(trifluorometil)fenil]-1H-piridin-4-il]-2-piridil]pirolidin-1-karboksamid; N-[4-[2-[2-(1-metoksi-1-metil-etil)pirolidin-1-il]-6-okso-1H-piridin-4-il]-2-piridil]acetamid; ili farmaceutski prihvatljiva sol istog.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili farmaceutski prihvatljiva sol istog, za primjenu u liječenju ili profilaksi bolesti.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili farmaceutski prihvatljiva sol istog, za primjenu u liječenju raka.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili farmaceutski prihvatljiva sol istog, za primjenu u liječenju dijabetesa tipa II.
14. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili farmaceutski prihvatljivu sol istog, i farmaceutski prihvatljiv razblaživač, nosač i/ili ekscipijens.
15. Farmaceutska kompozicija, koja sadrži terapijski efikasnu količinu spoja prema patentnom zahtjevu 1, ili farmaceutski prihvatljive soli istog, i drugi agens protiv raka odabran od alkilirajućeg agensa, antimetabolita, derivata kamptotecina protiv raka, agenasa protiv raka dobivenih iz biljaka, antibiotika, enzima, koordinacijskih kompleksa platine, inhibitora tirozin kinaze, hormona, hormonskih antagonista, monoklonskih antitijela, interferona, i modifikatora bioloških odgovora.
HRP20220571TT 2017-08-23 2018-08-23 Spoj piridilpiridona HRP20220571T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187544 2017-08-23
EP18759308.2A EP3672941B1 (en) 2017-08-23 2018-08-23 Pyridylpyridone compounds
PCT/EP2018/072788 WO2019038387A1 (en) 2017-08-23 2018-08-23 PYRIDYLPYRIDONE COMPOUNDS

Publications (1)

Publication Number Publication Date
HRP20220571T1 true HRP20220571T1 (hr) 2022-06-10

Family

ID=59686881

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220571TT HRP20220571T1 (hr) 2017-08-23 2018-08-23 Spoj piridilpiridona

Country Status (19)

Country Link
US (2) US11219618B2 (hr)
EP (2) EP3672941B1 (hr)
JP (2) JP7199737B2 (hr)
KR (1) KR20200043413A (hr)
CN (3) CN116891431A (hr)
AU (2) AU2018320416B2 (hr)
CA (1) CA3072974A1 (hr)
DK (1) DK3672941T3 (hr)
ES (1) ES2910839T3 (hr)
HR (1) HRP20220571T1 (hr)
HU (1) HUE058977T2 (hr)
IL (3) IL302356A (hr)
LT (1) LT3672941T (hr)
PL (1) PL3672941T3 (hr)
PT (1) PT3672941T (hr)
RS (1) RS63161B1 (hr)
SI (1) SI3672941T1 (hr)
TW (2) TWI787335B (hr)
WO (1) WO2019038387A1 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020124116A (ru) 2017-12-22 2022-01-25 Хиберселл, Инк. Производные арил-бипиридинамина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
US11801238B2 (en) 2020-11-25 2023-10-31 Deciphera Pharmaceuticals, Llc Anti-viral activity of VPS34 inhibitors
AU2022326573A1 (en) * 2021-08-13 2024-02-15 Deciphera Pharmaceuticals, Llc Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2485166A1 (en) * 2002-05-21 2003-12-04 Amgen Inc. Substituted pyrimidinone and pyridinone compounds
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
JP2014500308A (ja) 2010-12-21 2014-01-09 ノバルティス アーゲー Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物
PL2655375T3 (pl) 2010-12-23 2015-05-29 Sanofi Sa Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
WO2013185284A1 (en) * 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
BR112016016289B1 (pt) * 2014-01-14 2023-02-07 Takeda Pharmaceutical Company Limited Heteroaris e usos dos mesmos
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2016001789A1 (en) * 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
PT3416945T (pt) 2016-02-19 2020-09-11 Sprint Bioscience Ab Compostos de 6-aril-4-(morfolin-4-il)-1h-piridina-2-ona úteis para o tratamento do cancro e da diabetes
WO2017140843A1 (en) 2016-02-19 2017-08-24 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes

Also Published As

Publication number Publication date
EP3672941B1 (en) 2022-02-09
IL272805B (en) 2022-06-01
TW201912630A (zh) 2019-04-01
EP3672941A1 (en) 2020-07-01
CN116903526A (zh) 2023-10-20
CA3072974A1 (en) 2019-02-28
AU2018320416B2 (en) 2023-08-03
ES2910839T3 (es) 2022-05-13
RU2020110504A (ru) 2021-09-23
EP4056556A1 (en) 2022-09-14
DK3672941T3 (da) 2022-05-09
WO2019038387A1 (en) 2019-02-28
IL272805A (en) 2020-04-30
IL292485B2 (en) 2023-09-01
US20220218688A1 (en) 2022-07-14
CN111094244B (zh) 2023-07-11
PL3672941T3 (pl) 2022-06-13
JP2023021276A (ja) 2023-02-10
TWI787335B (zh) 2022-12-21
LT3672941T (lt) 2022-07-11
RU2020110504A3 (hr) 2022-02-24
TW202308996A (zh) 2023-03-01
CN111094244A (zh) 2020-05-01
US11219618B2 (en) 2022-01-11
IL302356A (en) 2023-06-01
IL292485B1 (en) 2023-05-01
JP2020531486A (ja) 2020-11-05
HUE058977T2 (hu) 2022-09-28
JP7199737B2 (ja) 2023-01-06
AU2023258375A1 (en) 2023-11-23
US20200289496A1 (en) 2020-09-17
PT3672941T (pt) 2022-04-14
RS63161B1 (sr) 2022-05-31
CN116891431A (zh) 2023-10-17
IL292485A (en) 2022-06-01
AU2018320416A8 (en) 2020-04-09
KR20200043413A (ko) 2020-04-27
SI3672941T1 (sl) 2022-07-29
AU2018320416A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
US20220331297A1 (en) Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
HRP20201400T1 (hr) Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa
HRP20220571T1 (hr) Spoj piridilpiridona
HRP20160852T1 (hr) Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
KR102534028B1 (ko) 트리아졸로피리미딘 화합물 및 그의 용도
HRP20210949T1 (hr) Spojevi i sastavi za moduliranje aktivnosti egfr mutant kinaze
HRP20231614T1 (hr) Spojevi pirolotriazina kao tam inhibitori
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
HRP20191027T1 (hr) Derivati imidazopiridina kao inhibitori tiposinskih receptora kinaza
RU2008138993A (ru) Производные хинолина
HRP20180341T1 (hr) Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd
JP2014506599A5 (hr)
HRP20120748T1 (hr) Heterocikliäśki spoj i farmaceutski sastavi koji ga sadrže
JP2010513444A5 (hr)
HRP20161286T1 (hr) Novi anti-invazivni spojevi
HRP20171655T1 (hr) Derivati aminopirimidina za upotrebu kao modulatori aktivnosti kinaze
SI2861579T1 (en) Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
CA2987054A1 (en) Inhibitors of bruton's tyrosine kinase
JP2016528298A5 (hr)
HRP20120762T1 (hr) Tetrasupstituirani piridazini kao inhibitori hedgehog puta
JP2022553351A (ja) Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン
JP2019505595A5 (hr)